viewBalchem Corporation

Balchem Corporation Reports Record Earnings


For the quarter ended June 30, 2010, Balchem Corporation (Nasdaq:BCPC) reported record net earnings of US$8.3 million, an increase of 21.4% over the same period in 2009 while net sales rose by 16% to $61.5 million. As a result, diluted net earnings per share increased 16.7% to $0.28 from $0.24 for the same period the previous year.  Balchem attributed the strong growth in revenues and earnings to a strong quarter for its Food, Pharma & Nutrition segment, and its continued focus on both organic and acquisitive growth.

All three of Balchem`s segments exhibited strong sales growth for the quarter.

 The Food, Pharma & Nutrition segment, which provides granulation and agglomeration solutions to human food, grew sales by 16.4% from last year`s comparable quarter to $10.6 million.

The Animal Nutrition & Health segment, a manufacturer and supplier of animal health products, posted a 16.8% sales increase from last year`s comparable quarter to $5.9 million. 

The ARC Specialty Products segment, which provides specialty chemicals for the healthcare industry, increased sales by 12.4% from last year`s comparable quarter to $10.2 million. 

For the six months ended June 30, 2010, Balchem posted $121.4 million in consolidated sales, a 14.5% increase from the same period the previous year.  Net earnings for the same period increased 18.4% to $15.4 million, while diluted earnings per share increased to $0.52 from $0.45. 

Balchem`s balance sheet  stayed healthy as its cash balance increased from $46.4 million in December to $50.4 million on June 30, with a net working capital of $77.1 million.  

 Dino A. Rossi, Balchem`s CEO, expressed optimism for the rest of 2010 as the global economy shows signs of improvement and expects continued improvements in sales and net earnings . 
Blachem rose 1.3% on the NASDAQ against a falling market.

Quick facts: Balchem Corporation

Price: 119.36 USD

Market: NASDAQ
Market Cap: $3.87 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Bionomics' positive pharmacokinetic results confirms it can begin second...

Bionomics Limited (ASX:BNO) (OTCQB:BNOEF) Executive Chairman Errol De Souza tells Proactive tells Proactive the Adelaide, Australia- based biopharmaceutical company has received positive pharmacokinetic results from a 7-day dosing study to treat PTSD, using its new formulation of BNC210. De...

1 day, 8 hours ago

2 min read